National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry
New York, NY – November 7, 2025 – Following a challenge submitted by Pfizer, Inc., BBB National Programs’ National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry.
Pfizer and BridgeBio sell prescription medication to treat transthyretin amyloid cardiomyopathy, a progressive and fatal disease caused by the buildup of a protein called transthyretin (TTR) in the heart and other organs.
At issue for NAD were challenged express and implied claims that BridgeBio’s Attruby product is superior to Pfizer’s Vyndamax because it offers greater TTR stabilization rates. Pfizer contends these claims are misleading, citing correspondence from the FDA.
BridgeBio declined to participate in the NAD self-regulatory process. Accordingly, NAD will refer the matter to the appropriate government agency and to the platforms on which BridgeBio’s advertising appeared and NAD has a reporting relationship.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Pursuant to NAD/NARB Procedures, this release may not be used for promotional purposes.
Pfizer and BridgeBio sell prescription medication to treat transthyretin amyloid cardiomyopathy, a progressive and fatal disease caused by the buildup of a protein called transthyretin (TTR) in the heart and other organs.
At issue for NAD were challenged express and implied claims that BridgeBio’s Attruby product is superior to Pfizer’s Vyndamax because it offers greater TTR stabilization rates. Pfizer contends these claims are misleading, citing correspondence from the FDA.
BridgeBio declined to participate in the NAD self-regulatory process. Accordingly, NAD will refer the matter to the appropriate government agency and to the platforms on which BridgeBio’s advertising appeared and NAD has a reporting relationship.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Pursuant to NAD/NARB Procedures, this release may not be used for promotional purposes.